$OMER
OMEROS CORP

2023 Q1 Form 10-K Financial Statement

#000155837023003575 Filed on March 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.10M $13.59M $50.67M
YoY Change 1.31% -75.22% -7.61%
% of Gross Profit
Research & Development $24.61M $26.55M $112.7M
YoY Change 2.17% -77.65% -5.1%
% of Gross Profit
Depreciation & Amortization $186.0K $163.0K $952.0K
YoY Change -33.09% -49.69% -31.31%
% of Gross Profit
Operating Expenses $24.61M $40.14M $112.7M
YoY Change 2.17% -76.88% -5.1%
Operating Profit -$35.71M -$163.4M
YoY Change 1.9% -5.89%
Interest Expense $7.933M -$7.903M $22.70M
YoY Change 60.55% -59.82% 15.42%
% of Operating Profit
Other Income/Expense, Net $3.963M $1.993M $4.062M
YoY Change 703.85% 14.54% 133.45%
Pretax Income -$39.68M -$46.05M -$182.0M
YoY Change 0.48% -75.96% -4.97%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$33.70M $128.7M $47.40M
YoY Change 2.09% -33.72% -75.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.54 $0.76
Diluted Earnings Per Share -$0.54 $2.05 $0.76
COMMON SHARES
Basic Shares Outstanding 62.83M 62.73M 62.74M
Diluted Shares Outstanding 62.83M 62.74M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.5M $194.9M $194.9M
YoY Change 161.21% 23.94% 23.94%
Cash & Equivalents $3.800M $11.00M $11.01M
Short-Term Investments $367.7M $183.9M $183.9M
Other Short-Term Assets $6.708M $6.300M $6.300M
YoY Change -12.0% -23.32% -23.32%
Inventory
Prepaid Expenses
Receivables $38.67M $241.8M $241.8M
Other Receivables $302.0K $255.0K $255.0K
Total Short-Term Assets $417.0M $443.2M $443.2M
YoY Change 98.38% 78.76% 78.76%
LONG-TERM ASSETS
Property, Plant & Equipment $22.36M $23.25M $23.25M
YoY Change -8.22% -22.5% -22.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.054M $1.054M $1.054M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $143.1M $147.7M $147.7M
YoY Change -10.03% -13.76% -13.76%
TOTAL ASSETS
Total Short-Term Assets $417.0M $443.2M $443.2M
Total Long-Term Assets $143.1M $147.7M $147.7M
Total Assets $560.1M $591.0M $591.0M
YoY Change 51.69% 40.95% 40.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.446M $5.989M $5.989M
YoY Change -12.24% -55.31% -55.31%
Accrued Expenses $30.82M $30.55M $34.44M
YoY Change 29.52% -7.8% -10.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $97.50M $95.96M $95.96M
YoY Change 14707.87%
Total Short-Term Liabilities $139.2M $136.4M $136.4M
YoY Change 296.94% 163.34% 163.34%
LONG-TERM LIABILITIES
Long-Term Debt $344.3M $346.5M $346.5M
YoY Change 9.67% 10.54% 10.54%
Other Long-Term Liabilities $21.74M $22.42M $22.42M
YoY Change -13.8% -25.88% -25.88%
Total Long-Term Liabilities $366.0M $368.9M $368.9M
YoY Change 7.93% 7.33% 7.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $139.2M $136.4M $136.4M
Total Long-Term Liabilities $366.0M $368.9M $368.9M
Total Liabilities $505.2M $505.3M $505.3M
YoY Change 35.01% 27.76% 27.76%
SHAREHOLDERS EQUITY
Retained Earnings -$669.4M -$635.7M
YoY Change -6.52% -6.94%
Common Stock $724.4M $721.4M
YoY Change 1.85% 2.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.94M $85.68M $85.68M
YoY Change
Total Liabilities & Shareholders Equity $560.1M $591.0M $591.0M
YoY Change 51.69% 40.95% 40.95%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$33.70M $128.7M $47.40M
YoY Change 2.09% -33.72% -75.6%
Depreciation, Depletion And Amortization $186.0K $163.0K $952.0K
YoY Change -33.09% -49.69% -31.31%
Cash From Operating Activities $174.5M -$25.38M -$86.50M
YoY Change -1248.56% 39.35% -21.16%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $13.00K $113.0K
YoY Change -117.57% -59.21%
Acquisitions
YoY Change
Other Investing Activities -$181.3M -$108.5M -$127.5M
YoY Change 136.07% -196.43% -165.7%
Cash From Investing Activities -$181.3M -$108.5M -$127.6M
YoY Change 136.07% -196.51% -165.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -388.0K -651.0K 124.2M
YoY Change -340.99% -19.63% 1866.26%
NET CHANGE
Cash From Operating Activities 174.5M -25.38M -86.50M
Cash From Investing Activities -181.3M -108.5M -127.6M
Cash From Financing Activities -388.0K -651.0K 124.2M
Net Change In Cash -7.180M -134.5M -89.80M
YoY Change -92.18% -244.04% -199.44%
FREE CASH FLOW
Cash From Operating Activities $174.5M -$25.38M -$86.50M
Capital Expenditures $0.00 $13.00K $113.0K
Free Cash Flow $174.5M -$25.40M -$86.61M
YoY Change -1248.56% 39.99% -21.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.41
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-838000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
648000
CY2022Q4 omer Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
5926000
CY2021Q4 omer Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
9995000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9234000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://www.omeros.com/20221231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62628855
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62828765
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
590969000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
CY2022 dei City Area Code
CityAreaCode
206
CY2022 dei Local Phone Number
LocalPhoneNumber
676-5000
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
OMER
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
165588454
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62828765
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Location
AuditorLocation
Seattle, Washington
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11009000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100808000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
183909000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
56458000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.118
CY2022Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
28797000
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-34475
CY2022 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
CY2021Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44319000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
213221000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6300000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8216000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
443236000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
247956000
CY2022Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
123425000
CY2021Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
140251000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21762000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28276000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1492000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2022Q4 us-gaap Assets
Assets
590969000
CY2021Q4 us-gaap Assets
Assets
419268000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5989000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13400000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30551000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q4 us-gaap Senior Notes Current
SeniorNotesCurrent
94381000
CY2022Q4 omer Royalty Obligation Current
RoyaltyObligationCurrent
1152000
CY2022Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
4310000
CY2021Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
5255000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
136383000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51789000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
220906000
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
313458000
CY2022Q4 omer Royalty Liabilities Non Current
RoyaltyLiabilitiesNonCurrent
125126000
CY2022Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
22426000
CY2021Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
29126000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
444000
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1115000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62828765
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62628855
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
628000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
626000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
720773000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
706288000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635717000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683134000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
85684000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419268000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112721000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118775000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107612000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50668000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54842000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
49306000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
163389000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
173617000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
156918000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-163389000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-173617000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-156918000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13374000
CY2022 us-gaap Interest Expense
InterestExpense
22702000
CY2021 us-gaap Interest Expense
InterestExpense
19669000
CY2020 us-gaap Interest Expense
InterestExpense
26751000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
4062000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
1740000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
654000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-182029000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-191546000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-196389000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23256000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-182029000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-191546000
CY2020 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-173133000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
229446000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
385781000
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
35072000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
47417000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
194235000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-138061000
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.90
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.90
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.07
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.07
CY2020 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.02
CY2020 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.02
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
3.66
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.66
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
6.19
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
6.19
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.61
CY2020 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.61
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.12
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.12
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
175066000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62737091
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62737091
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62344100
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62344100
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57176743
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57176743
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-109021000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93675000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5022000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
155000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
14770000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
61628000
CY2020 omer Adjustments To Additional Paid In Capital For Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalForPurchaseOfCappedCalls
23223000
CY2020 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-22073000
CY2020 omer Adjustments To Additional Paid In Capital For Termination Capped Call Contracts
AdjustmentsToAdditionalPaidInCapitalForTerminationCappedCallContracts
8387000
CY2020 omer Adjustments To Additional Paid In Capital For Tax Benefit Related To Issuance Of Convertible Senior Debt Net Of Extinguishment
AdjustmentsToAdditionalPaidInCapitalForTaxBenefitRelatedToIssuanceOfConvertibleSeniorDebtNetOfExtinguishment
12011000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-138061000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-120752000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8382000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
91000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
241000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
17539000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
194235000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
415000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
14072000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
47417000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
85684000
CY2022 us-gaap Profit Loss
ProfitLoss
47417000
CY2021 us-gaap Profit Loss
ProfitLoss
194235000
CY2020 us-gaap Profit Loss
ProfitLoss
-138061000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
14072000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
17630000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14925000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
310563000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1830000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1696000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11649000
CY2022 omer Non Cash Interest Expense On Royalty Obligation
NonCashInterestExpenseOnRoyaltyObligation
1695000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
952000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1386000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1616000
CY2022 omer Non Cash Adjustments On Buyout Of Finance Leases
NonCashAdjustmentsOnBuyoutOfFinanceLeases
64000
CY2022 omer Remeasurement Adjustment On Contract Royalty Asset
RemeasurementAdjustmentOnContractRoyaltyAsset
18634000
CY2022 omer Interest On Contract Royalty Asset
InterestOnContractRoyaltyAsset
14457000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
454000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-13374000
CY2020 omer Deferred Income Taxes Excluding Discontinued Operations
DeferredIncomeTaxesExcludingDiscontinuedOperations
-12011000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
34314000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-31344000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11009000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100808000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1324000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5568000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4024000
CY2022 omer Increase Decrease In Contract Royalty Asset Current
IncreaseDecreaseInContractRoyaltyAssetCurrent
-65439000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10665000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14640000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-19736000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86483000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109722000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-100086000
CY2021 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
125993000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
429045000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32006000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
133194000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
301594000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
100000000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
66446000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
277000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
283000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-127564000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
193710000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67031000
CY2022 omer Proceeds From Royalty Obligation
ProceedsFromRoyaltyObligation
125000000
CY2022 omer Principal Payments On Royalty Obligations
PrincipalPaymentsOnRoyaltyObligations
417000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
225030000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6785000
CY2020 omer Payment For Purchase Of Capped Call
PaymentForPurchaseOfCappedCall
23223000
CY2020 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
125638000
CY2020 omer Proceeds From Termination Of Capped Call Contracts
ProceedsFromTerminationOfCappedCallContracts
7549000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93675000
CY2020 omer Increase Decrease In Restricted Investments
IncreaseDecreaseInRestrictedInvestments
-99000
CY2022 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
415000
CY2021 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
8383000
CY2020 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
5022000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
750000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1823000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1195000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
241000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
124248000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6319000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174534000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-89799000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
90307000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7417000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100808000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10501000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3084000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10501000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
19178000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21971000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28811000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
17876000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
11603000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
40000
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
289000
CY2020 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
216000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 10.8pt;">General<span style="font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Omeros Corporation (“Omeros,” the “Company” or “we”) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. We marketed our first drug product OMIDRIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (phenylephrine and ketorolac intraocular solution) 1% / 0.3% for use during cataract surgery or intraocular lens replacement in the United States (the “U.S.”) until we sold OMIDRIA and related business assets on December 23, 2021 (see “Sale of OMIDRIA Assets” below for additional information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The lead drug candidate in our pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2 (“MASP-2”), the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused primarily on hematopoietic stem cell transplant-associated thrombotic microangiopathy (“HSCT-TMA”) and immunoglobulin A (“IgA”) nephropathy. Our pipeline of clinical-stage investigational agents also includes: our long-acting MASP-2 inhibitor, OMS1029, our inhibitor of mannan-binding lectin-associated serine protease-3 (“MASP-3”), OMS906, and our phophodiesterase 7 (“PDE7”) inhibitor, OMS527.</p>
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
194900000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
213200000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86500000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
47400000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
455000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
315000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 10.8pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include OMIDRIA contract royalty asset valuation, stock-based compensation expense, and accruals for clinical trials and manufacturing of drug product. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2022Q4 omer Lease Liability
LeaseLiability
26736000
CY2021Q4 omer Lease Liability
LeaseLiability
34381000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
3200000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
7800000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
5600000
CY2020 omer Percentage Of Total Sale Wholesalers
PercentageOfTotalSaleWholesalers
1
CY2021 omer Percentage Of Total Sale Wholesalers
PercentageOfTotalSaleWholesalers
1
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17221985
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18823760
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15614919
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2022Q4 omer Royalty Obligation Capitalized Accrued Interest
RoyaltyObligationCapitalizedAccruedInterest
1695000
CY2022Q4 omer Milestone Payment Receivable
MilestonePaymentReceivable
200000000
CY2022Q4 omer Royalty Receivables
RoyaltyReceivables
12966000
CY2021Q4 omer Royalty Receivables
RoyaltyReceivables
1035000
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
35470000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
255000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1650000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
213221000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2022Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
0
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2000000.0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000000.0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100800000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
11040000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10764000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9548000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9033000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1492000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000.0
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2022Q4 omer Royalty Obligation Principal Payments
RoyaltyObligationPrincipalPayments
417000
CY2022Q4 omer Royalty Obligations
RoyaltyObligations
126278000
CY2022 omer Contractual Interest Expense On Royalty Obligation
ContractualInterestExpenseOnRoyaltyObligation
2900000
CY2022 omer Non Cash Contractual Interest Expense On Royalty Obligation
NonCashContractualInterestExpenseOnRoyaltyObligation
1700000
CY2022 omer Cash Contractual Interest Expense On Royalty Obligation
CashContractualInterestExpenseOnRoyaltyObligation
1200000
CY2022Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.094
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6665000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3706000
CY2022Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
5536000
CY2021Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
2430000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5172000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5172000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4871000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
338000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4425000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7455000
CY2022Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
3209000
CY2021Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
3916000
CY2021Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
8442000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
673000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1675000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30551000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4743000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
315287000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
6572000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
313458000
CY2022Q3 omer Royalty Obligations
RoyaltyObligations
125000000
CY2022Q4 omer Royalty Obligation Principal Payments Due Next Twelve Months
RoyaltyObligationPrincipalPaymentsDueNextTwelveMonths
1152000
CY2022Q4 omer Royalty Obligation Interest Payments Due Next Twelve Months
RoyaltyObligationInterestPaymentsDueNextTwelveMonths
11848000
CY2022Q4 omer Royalty Obligation Payments Due Next Twelve Months
RoyaltyObligationPaymentsDueNextTwelveMonths
13000000
CY2022Q4 omer Royalty Obligation Principal Payments Due Year Two
RoyaltyObligationPrincipalPaymentsDueYearTwo
8576000
CY2022Q4 omer Royalty Obligation Interest Payments Due Year Two
RoyaltyObligationInterestPaymentsDueYearTwo
11424000
CY2022Q4 omer Royalty Obligation Payments Due Year Two
RoyaltyObligationPaymentsDueYearTwo
20000000
CY2022Q4 omer Royalty Obligation Principal Payments Due Year Three
RoyaltyObligationPrincipalPaymentsDueYearThree
14641000
CY2022Q4 omer Royalty Obligation Interest Payments Due Year Three
RoyaltyObligationInterestPaymentsDueYearThree
10359000
CY2022Q4 omer Royalty Obligation Payments Due Year Three
RoyaltyObligationPaymentsDueYearThree
25000000
CY2022Q4 omer Royalty Obligation Principal Payments Due Year Four
RoyaltyObligationPrincipalPaymentsDueYearFour
16081000
CY2022Q4 omer Royalty Obligation Interest Payments Due Year Four
RoyaltyObligationInterestPaymentsDueYearFour
8919000
CY2022Q4 omer Royalty Obligation Payments Due Year Four
RoyaltyObligationPaymentsDueYearFour
25000000
CY2022Q4 omer Royalty Obligation Principal Payments Due Year Five
RoyaltyObligationPrincipalPaymentsDueYearFive
17664000
CY2022Q4 omer Royalty Obligation Interest Payments Due Year Five
RoyaltyObligationInterestPaymentsDueYearFive
7336000
CY2022Q4 omer Royalty Obligation Payments Due Year Five
RoyaltyObligationPaymentsDueYearFive
25000000
CY2022Q4 omer Royalty Obligation Principal Payments Due After Year Five
RoyaltyObligationPrincipalPaymentsDueAfterYearFive
68164000
CY2022Q4 omer Royalty Obligation Interest Payments Due After Year Five
RoyaltyObligationInterestPaymentsDueAfterYearFive
10586000
CY2022Q4 omer Royalty Obligation Payments Due After Year Five
RoyaltyObligationPaymentsDueAfterYearFive
78750000
CY2022Q4 omer Royalty Obligation Principal Payments Due
RoyaltyObligationPrincipalPaymentsDue
126278000
CY2022Q4 omer Royalty Obligation Interest Payments Due
RoyaltyObligationInterestPaymentsDue
60472000
CY2022Q4 omer Royalty Obligation Payments Due
RoyaltyObligationPaymentsDue
186750000
CY2022 omer Number Of Options To Extend Lease
NumberOfOptionsToExtendLease
2
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2022Q1 omer Decrease In Right Of Use Asset Due To Early Operating Lease Termination
DecreaseInRightOfUseAssetDueToEarlyOperatingLeaseTermination
4700000
CY2022Q1 omer Decrease In Lease Liability Due To Early Operating Lease Termination
DecreaseInLeaseLiabilityDueToEarlyOperatingLeaseTermination
5200000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
500000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21762000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28276000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
945000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1009000
CY2022Q4 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
22707000
CY2021Q4 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
29285000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3888000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4607000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
422000
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1281
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1281
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1044
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1270
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6152000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
7364000
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
812000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1102000
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
174000
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
181000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
3191000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
3519000
CY2022 us-gaap Sublease Income
SubleaseIncome
1755000
CY2021 us-gaap Sublease Income
SubleaseIncome
1776000
CY2022 us-gaap Lease Cost
LeaseCost
8574000
CY2021 us-gaap Lease Cost
LeaseCost
10390000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
7072000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
7483000
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
790000
CY2021 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
939000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8312000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
495000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due Next Twelve Months
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
8807000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7031000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
321000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due Year Two
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
7352000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7088000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
150000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due Year Three
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
7238000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6870000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
60000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due Year Four
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
6930000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5837000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due Year Five
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDueYearFive
5837000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35138000
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1026000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Payments Due
LesseeOperatingAndFinanceLeaseLiabilityPaymentsDue
36164000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9279000
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
149000
CY2022Q4 omer Lessee Operating And Finance Lease Liability Undiscounted Excess Amount
LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
9428000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
25859000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
877000
CY2022Q4 omer Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
26736000
CY2022Q4 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
24200000
CY2022Q4 omer Development Milestone Payable
DevelopmentMilestonePayable
300000
CY2021Q4 omer Development Milestone Payable
DevelopmentMilestonePayable
500000
CY2020Q4 omer Development Milestone Payable
DevelopmentMilestonePayable
5500000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18939004
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
CY2020Q3 us-gaap Share Price
SharePrice
14.50
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93700000
CY2022 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
14165000
CY2021 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
14945000
CY2020 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
13777000
CY2022 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
-93000
CY2021 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
2685000
CY2020 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
1148000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14072000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17630000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14925000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12709887
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.61
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2742834
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.81
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
101160
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1478588
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.05
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13872973
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.02
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13454543
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.10
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
19000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9859720
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.12
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-19472000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3784000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-23256000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23256000
CY2022 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
3952000
CY2021 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
1006000
CY2020 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
11245000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4900000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23300000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
85887000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
143657000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
78992000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
66612000
CY2022Q4 omer Deferred Tax Asset Royalty Obligation
DeferredTaxAssetRoyaltyObligation
28938000
CY2022Q4 omer Deferred Tax Asset Research And Development Capitalization
DeferredTaxAssetResearchAndDevelopmentCapitalization
21864000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
12517000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11327000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
17862000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
243358000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
249453000
CY2022Q4 omer Deferred Tax Liabilities Gain On Discontinued Operation
DeferredTaxLiabilitiesGainOnDiscontinuedOperation
34883000
CY2021Q4 omer Deferred Tax Liabilities Gain On Discontinued Operation
DeferredTaxLiabilitiesGainOnDiscontinuedOperation
42212000
CY2022Q4 omer Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
4987000
CY2021Q4 omer Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6467000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
288000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
102000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
40158000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
48781000
CY2022Q4 omer Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
203200000
CY2021Q4 omer Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
200672000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
203200000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
201340000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
668000
CY2022Q4 omer Deferred Tax Asset Research And Development Capitalization
DeferredTaxAssetResearchAndDevelopmentCapitalization
21900000
CY2022 omer Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1900000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-19300000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.283
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.269
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.193
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.068
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.055
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.062
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.014
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.013
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.040
CY2022 omer Defined Contribution Plan Maximum Employer Matching Contribution
DefinedContributionPlanMaximumEmployerMatchingContribution
4000
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP

Files In Submission

Name View Source Status
0001558370-23-003575-index-headers.html Edgar Link pending
0001558370-23-003575-index.html Edgar Link pending
0001558370-23-003575.txt Edgar Link pending
0001558370-23-003575-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20221231.xsd Edgar Link pending
omer-20221231x10k.htm Edgar Link pending
omer-20221231x10k006.jpg Edgar Link pending
omer-20221231xex10d1.htm Edgar Link pending
omer-20221231xex10d11.htm Edgar Link pending
omer-20221231xex23d1.htm Edgar Link pending
omer-20221231xex31d1.htm Edgar Link pending
omer-20221231xex31d2.htm Edgar Link pending
omer-20221231xex32d1.htm Edgar Link pending
omer-20221231xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omer-20221231_cal.xml Edgar Link unprocessable
omer-20221231_def.xml Edgar Link unprocessable
omer-20221231_lab.xml Edgar Link unprocessable
omer-20221231_pre.xml Edgar Link unprocessable
omer-20221231x10k_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending